Subcutaneous veltuzumab regulatory update

FDA granted Orphan Drug designation to subcutaneous veltuzumab to treat pemphigus. The humanized anti-CD20 antibody has completed Phase II testing in non-Hodgkin’s lymphoma (NHL) and is in Phase I/II ...